drugset

Drugs / PF-05105679

Follow last change Sep 2023 re-read 2 minutes ago

PF-05105679

also known as (R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid · PF 5105679

Investigated by: Medical University of Vienna

Trials 1 · a red edge is where a trial was stopped

today NCT05935280 · Ph 0

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 0	NCT05935280	Jul → Sep 2023	—	Medical University of Vienna	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT01393652 Comparator	May → Sep 2011	—	Pfizer	Completed	No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	PF-05105679	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01393652 ↗ 1 NCT05935280 ↗
Known as	(R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid	“We have identified a moderately potent (IC50 = 103 nM), selective TRPM8 antagonist, PF-05105679 [(R)-3-[(1-(4-fluorophenyl)ethyl)(quinolin-3-ylcarbonyl)amino]methylbenzoic acid].” PMID 25125580 ↗ Aug 2014
Known as	PF 5105679	ChEMBL registry synonym — accepted as the source's own label CHEMBL3577885 ↗
Action	Inhibit	“Specific antagonist of the TRPM8 ion channel” NCT05935280 ↗
Modality	Small molecule	— CHEMBL3577885 ↗
Route	Other	“Pain induced by intradermal injection of increasingly cold fluid down to 3°C including PF-05105679 (specific TRPM8 antagonist).” NCT05935280 ↗